Elsevier

Pathology

Volume 38, Issue 5, October 2006, Pages 415-420
Pathology

Perivascular epithelioid cell tumour (PEComa) of the soft tissue

https://doi.org/10.1080/00313020600922504Get rights and content

Summary

Aims

PEComa is a rare tumour developing from perivascular epithelioid cells (PEC) and is characterised by positive immunoreactivity for HMB45. Since PEComas are tumours having both a spindle cell component and an epithelioid and giant cell component, as seen in many sarcomas, as well as having a wide distribution in various organs and soft tissue, we reviewed cases originally diagnosed as sarcomas of the soft tissue in our institution and screened them by immunostaining for HMB45.

Methods

Consecutive soft tissue sarcomas (31 tumours) retrieved from the Surgical Pathology file at our institution for a period of 3 years were submitted for immunostaining for HMB45. Cases with positive HMB45 immunostaining were submitted for further immunostaining for MARTI, CD68, S100 protein, cytokeratin AE1/3, EMA, vimentin, MSA and CD117.

Results

Of 31 sarcomas, three tumours in the group of 11 malignant fibrous histiocytomas (MFH) and unclassified sarcomas showed positive immunoreactivity for HMB45 and MART1 in 1-25% of tumour cells. The three tumours were located in the lower extremities and measured 8, 11 and 12 cm in diameter. Patient gender male:female was 2:1 and ages were 46, 56 and 60 years. Microscopically, the tumours were composed of a variable proportion of spindled cells, multinucleated cells and epithelioid cells disposed in diffuse sheets or nests. Mitotic figures and necrosis were frequent. The immunoreactivity was diffuse for CD68, focal for AE3 and EMA, negative or focal for MSA and CD117, and negative for S100 and AE1. All three patients developed lymph node or distant metastases and died of the disease within 1-2 years.

Conclusion

PEComa re-screened from the group of high grade sarcomas without definite differentiation range from pleomorphic to monomorphic cytohistopathological features. Immunostaining for HMB45 of unclassified sarcomas is useful fortheclassification of these tumours. They occur preferentially in the lower extremities and have a high malignant potential when associated with large size, tumoural necrosis and high mitotic activity.

References (34)

  • SaxenaA. et al.

    Molecular analysis of clonality of sporadic angiomyolipoma

    J Pathol

    (1999)
  • MartignoniG. et al.

    Renal angiomyolipoma with epithelioid sarcomatous transformation and metastases: demonstration of the same genetic defects in the primary and metastatic lesions

    Am J Surg Pathol

    (2000)
  • YamasakiS. et al.

    Monotypic epithelioid angiomyolipoma of the liver

    Histopathology

    (2000)
  • LauS.K. et al.

    Malignant monotypic epithelioid angiomyolipoma of the retroperitoneum

    Int J Surg Pathol

    (2003)
  • PanC.C. et al.

    Malignant perivascular epithelioid cell tumor involving the prostate

    Arch Pathol Lab Med

    (2003)
  • VangR. et al.

    Perivascular epithelioid cell tumor (‘PEComa’) of the uterus: a subset of HMB-45-positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumors

    Am J Surg Pathol

    (2002)
  • FolpeA.L. et al.

    Clear cell myomelanocytic tumor of the thigh: report of a unique case

    Am J Surg Pathol (Comment in Am J Surg Pathol 2001; 27: 1228

    (2002)
  • Cited by (25)

    • Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: A review and update

      2014, Human Pathology
      Citation Excerpt :

      A recent study reported melan A positivity in all 12 epithelioid mesotheliomas stained with the A103 anti–melan A antibody [118], but this observation was not confirmed in a subsequent investigation [119]. Both the A103 and the M2-7C10 clones react with PEComas and clear cell sarcomas [120-122]. Other anti–melan A mouse monoclonal antibodies that are commercially available include clones M2-9E3, 3H2639, ON.396, ON.397, and SPM342, but to my knowledge, no immunohistochemical studies have been published using these antibodies in the diagnosis of melanomas.

    View all citing articles on Scopus
    View full text